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Abstract
Isopeptides (ε -peptides) of lysine, with a given Mw and low polydispersity (10–400 units), were
synthesized to study the relationship between their chemical structure and biological effect. The
designed compounds were of high purity, low polydispersity and high stereochemical purity. The
effect of the compounds was tested on a human erythroleukemia cell line (K-562) and on four
transplantable mouse tumors (L1210 lymphoid leukemia, P38 macrophage derived tumor, Ehrlich
ascites carcinoma, Lewis lung tumor /LLT/). In case of the L1210 and P388 tumors and the Ehrlich
carcinoma, survival of the animals was used as an indicator of the effect. In case of the Lewis lung
tumor, the number and size of metastases in the lung and/or liver of treated and untreated mice
were used as indicators. The polymers of polymerisation degree 80–120 (Mw 10.2–15.4 KD)
showed the strongest antiproliferative effect both on K562 cells and the tumors growing in vivo.
This effect was manifest with a significantly higher survival rate as compared to the control (L1210,
P38, Ehrlich ascites), furthermore, by a decrease in the number and size of liver and lung metastases
(LLT).
Introduction
The biological activity of poly-cations includes the immu-
noglobulin production stimulatory activity of epsilon
poly-L-lysine. This compound also enhances interferon
beta production, without stimulating cell proliferation
[1]. On the other hand, alpha-poly-L-lysine enhances the
proliferation of astrocytes in culture [2].
Clavicepamines are lysine-rich basic proteins isolated
from cultures of ergot (Claviceps purpurea). These proteins
could be fractionated to yield compounds of Mw 2–17 kD
with a high lysine content (between 30–95 mole%). Bio-
logical investigation of these compounds showed a cell-
proliferation retarding effect in animal tumors, without
toxic side effects [3]. Structure determinations indicate
that ε -lysine (poly) peptides are the fundamental structur-
al units of clavicepamines.
In the present study, active oligomers for polycondensa-
tion have been prepared by a process which protected the
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carboxyl groups with active ester groups, and the peptide
coupling was carried out at a considerably higher rate than
the aminolysis of the protecting active ester group. This
coupling method provides a higher degree of activation
than the active ester method [4].
We found that the "backing off" activation method is
highly applicable for preparing isopeptides and salts con-
sisting of diamino carboxylic acids. For temporary protec-
tion and simultaneous activation of the COOH groups, p-
nitrophenylester is the most suitable.
The biological activity of the polyisolysines prepared in
our laboratory was studied in vitro and in vivo.
Materials and methods
Enzymatic cleavage of lysine isopeptides
Enzymes: trypsin (2×  cryst. lyophil.), chymotrypsin (N:
14.52%), papain (cryst.), pronase-P (protease from Strep-
tomyces griseus), subtilisin (cryst.), carboxypeptidase-B (N:
15.4%) were obtained from SERVA Entwicklungslabor
(Heidelberg, Germany); hog kidney leucineaminopepti-
dase from Koch Light Lab. Ltd. (USA).
Reference substrates
human serum albumin (lyophil.), benzyloxy-carbonyl-
glycyl-L-phenylalanine, leucineamide hydrochloride
(SERVA Entwicklungslabor, Heidelberg, Germany).
Compounds labelling of SZTP:Polyiso-L-lysines produced 
by our method (see Table 1)
SZTP-14: Polyiso-L-lysine HBr salt, molecular weight cal-
culated on free bases: 12700± 200, polydispersity: 3.7
(number average/weight average).
Further characterisation of SZTP-14.
The free polymer was available as HBr salt.
Br content: 37.7% (calc.), 36.8% (found).
A254 (0 (i.e. no UV absorbance).
It was purified by precipitation from alcohol with ether.
(α )20 D (32.4° (C = 2; water)
Mw = 12700 D ± 200
SZTP-15: Polyiso-L-lysine HBr salt, molecular weight cal-
culated on free bases: 11600 ± 200.
SZTP-16: Polyiso-L-lysine HBr salt, molecular weight cal-
culated on free bases: 13400 ± 200.
SZTP-l7: Polyiso-L-lysine HBr salt, molecular weight cal-
culated on free bases: 14500 ± 200.
SZTO-18: Polyiso-L-ornithine HBr salt, molecular weight
calculated on free bases: 8900 ± 200.
H-17: Polyisolysine produced according to Hull et al. [5].
K-17: Polyisolysine produced according to Kushawa et al.
[6]
A-3: α -Polylysine. Mw = 300 kD (SIGMA Ltd., USA)
Method of digestion and analysis
Digestion of the oligomers, polymers and the reference
substrates by different enzymes was followed by paper
electrophoresis. Incubation mixtures containing 0.1–2%
of substrates in suitable buffers (pH 7 for trypsin and pH
8.5 for the others) were kept at 37°C in small test tubes.
The reaction was initiated by the addition of the enzyme.
1–10 µl aliquots of the digests were taken at 0.2 and 24 h
respectively, and were applied directly to Whatman No. 1
paper. Electrophoretic patterns were obtained in a hori-
zontal electrophoretic assembly at 1500 V. Digestion was
indicated by the appearance of new lysine ninhydrin-pos-
itive spots, by the change in intensity of ninhydrin color
with time and finally, and by the disappearance of the
starting materials.
In vitro studies on cell proliferation
Cells: K-562 human erythroleukemia cell line (Karolinska
Institute, Stockholm) was used.
Cell number: 50 ×  103/ml, in 5–6 ml medium containing
glass test tubes.
Number of probes: 3 test tubes/dose.
Table 1: Characterization of isopolylysines (å-poly-lysines-HBr)
Charge No Preparationmethod Mw (± 300) Polym. 
Degree (± 2)
K-17 Kushawa (6) 9400 73
H-17 Hull (5) 900–3200 7–23
SZTP-14 ,,backing off" ONp 12700 99
SZTP-15 Dialyzed (H2O) 11600 90
SZTP-16 Dialyzed (NaCl) 13400 105
SZTP-17 Ion exchanged 14500 113
SZTP-18 Kushawa (6) OPep 9500 74Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/4
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Medium: Parker's M-199 supplemented with 10 % fetal
bovine serum (Flow Laboratories, Irvine, Scotland).
Temperature, atmosphere: 37°C, 5% CO2 + 95% air.
Treatment: 24 h after the dilution of cell cultures.
Doses: 1–10–100 ug/ml
Evaluation: Cell counts 24, 48, 72 and 96 h after the dilu-
tion of cultures, using Buerker's chamber.
Cells were counted in 3 test tubes per dose and in 3 test
tubes as control at each time-point.
Table 2: Effect of various polylysines on K-562 cell cultures Cell number: ×  103 /ml culture medium (average ± SD)
Compound SZTP-14 SZTP-15
dose (µg/ml) Control 1 10 100 Control 1 10 100
Hours after treat-
ment 24
120 ± 10 93.3 ± 11 90 ± 20 0 120 ± 15 100 ± 11 60 ± 15 50 ± 15
48 223.3 ± 156.6 ± 5 83.3 ± 5 0 190 ± 11 140 ± 15 120 ± 19 20 ± 5
72 240 ± 17 173.3 ± 136.6 ± 15 0 250 ± 15 190 ± 10 110 ± 25 10 ± 5
Compound SZTP-16 SZTP-17
dose (µg/ml) Control 1 10 100 Control 1 10 100
Hours after treat-
ment 24
130 ± 10 120 ± 13 120 ± 14 120 ± 15 150 ± 15 130 ± 12 120 ± 10 120 ± 10
48 200 ± 15 210 ± 20 160 ± 17 120 ± 10 220 ± 18 210 ± 16 200 ± 17 190 ± 14
72 260 ± 20 280 ± 22 240 ± 23 140 ± 20 280 ± 20 280 ± 18 260 ± 20 210 ± 20
Compound SZTO-18 H-17
dose (µg/ml) Control 1 10 100 Control 1 10 100
Hours after treat-
ment 24
150 ± 14 140 ± 12 120 ± 10 100 ± 11 150 ± 14 120 ± 10 130 ± 11 110 ± 10
48 230 ± 18 210 ± 17 160 &#177; 
15
130 ± 15 230 ± 18 214 ± 14 240 ± 12 210 ± 16
72 280 ± 20 260 ± 22 230 ± 20 180 ± 20 260 ± 22 290 ± 22 280 ± 21 270 ± 20
Compound K-17 A-3
dose (µg/ml) Control 1 10 100 Control 1 10 100
Hours after treat-
ment 24
130 ± 12 120 ± 11 135 ± 11 110 ± 5 120 ± 11 120 ± 10 120 ± 10 12" ± 11
48 200 ± 15 220 ± 15 240 ± 10 210 ± 10 240 ± 14 110 ± 51 1 0  ± 10 110 ± 5
72 280 ± 17 280 ± 20 290 ± 19 290 ± 19 290 ± 20 110 ± 7 110 ± 51 0 0  ± 10Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/4
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In vivo studies on the effect of SZTP 14
a) L1210 tumor
Origin of tumor: Chester Beatty Institute, London.
Animal strain: DBA/2 inbred mice, own breed.
Weight and sex of animals: 20–23 g females, 5 animals/
group.
Tumor cell number: 105/animal injected intraperitoneal-
ly.
Treatment: 50 mg/kg, injected intraperitoneally 24 h after
tumor inoculation, for 8 days, once a day.
Control group: physiological saline solution, 0.2 ml intra-
peritoneally.
Evaluation: survival of animals.
b) P-388 ascites tumor
Origin of tumor: National Institute of Oncology, Buda-
pest, Hungary.
Animal strain. BDF/1 hybrid mice, own breed.
Weight and sex of animals: 20–23 g, males 5 mice/group.
Cell number: 2.8 ×  106/animal, injected intraperitoneally.
Treatment: 10 mg/kg injected intraperitoneally daily,
started 24 h after tumor inoculation.
Control: 0.2 ml of physiological saline solution daily, in-
traperitoneally.
Evaluation: survival of animals.
c) Ehrlich ascites tumor
Table 3: The effect of 50 mg/kg daily treatment on the survival of 
DBA/2 mice inoculated with L1210
Days after inocula-
tion









Table 4: Number of surviving animals, untreated and treated with SZTP-14 on subsequent days after inoculation of Ehrlich ascites 
carcinoma
Control 50 mg/kg 75 mg/kg
Days after inoculation ?? ? ? ? ?
16 5 5 4* 555
17 5 4 4 5 5 5
18 5 4 4 5 5 5
19 3 2 4 5 5 5
20 2 2 4 5 5 5
21 2 2 4 5 5 5
22 0 1 4 5 5 5
23 0 0 4 5 5 5
24 0 0 4 5 5 5
|
?
50 0 0 4 4 5 5
51 0 0 4 4 5 5
52 0 0 4 4 5 5
53 0 0 4 4 5 5
54 0 0 4 4 5 5
55 0 0 4 4 4 4
* = died of unrelated causesCancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/4
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Origin of tumor: National Insitute of Oncology, Budapest,
Hungary.
Animal strain: Swiss mice, not inbred, own breed.
Weight and sex of animals: 20 g, 5 males and 5 females/
group.
Tumor cell number: 106/animal
Treatment: 50 mg/kg and 75 mg/kg resp., injected intra-
peritoneally daily, started 24 h after tumor inoculation,
for 20 days.
Control: 0.2 ml of physiological saline solution, daily, in-
traperitoneally.
Evaluation: measurement of body weight, daily follow up
on survival. Animals alive 55 days after tumor inoculation
were sacrified, autopsied, amount of ascites measured, oc-
casional solid tumor formation in the peritoneal cavity
registered.
Inhibition of tumor metastases
Lewis lung tumor (LLT) inoculation into the spleen.
Origin of the tumor: NCI, Bethesda, MD, USA.
Animal strain: inbred C57Bl mice, LATI, Gödöllõ, Hunga-
ry.
Weight and sex of animals: 20–23 g females (6 controls
and 4 treated).
Tumor cell number: 5 ×  106 LLT cells inoculated into the
spleen.
Treatment: 75 mg/kg for 8 days, started 25 h after tumor
inoculation.
Evaluation: animals were killed and liver metastases
counted on the 9th day after tumor inoculation.
Lewis lung tumor (LLT) inoculation into thigh muscle.
Animal strain: C57Bl inbred, LATI, Gödöllõ, Hungary.
Weight and sex of animals: 20–22 g females.
Number of animals: 5/group.
Tumor cells
5 ×  105 cells/animal, injected intramuscularly into the
thigh muscles. Ten days after tumor inoculation the tu-
mor-bearing extremity was removed. After the operation,
between the 11th and 17th days subsequent to tumor in-
oculation, a daily intraperitoneal dose of 50 mg/kg SZTP-
14 was given. Controls intraperitoneally received 0.2 ml
of physiological saline solution daily.
Evaluation
Animals were sacrified on the 18th day after tumor inocu-
lation. The number and average volume of the lung me-
tastases were determined under a stereomicroscope.
Results
In vitro studies
Table 2 shows the effect of polyisolysines produced by
various processes and of α -polylysine on the proliferation
of K-562 cells. SZTP-14, SZTP-15, SZTP-16, SZTP-17 and
SZTP-18 – but especially SZTP-14 – treatment resulted in
a significant, dose-dependent inhibition of cell prolifera-
tion. It was noteworthy that even 1 µg/ml treatment
caused a well-defined antiproliferative effect.
However, H-17 and K-17 did not influence the prolifera-
tion of K-562 cells. á-polylysine caused the stagnation of
cell number when compared to the control, but did not
Table 5: Ascites and solid tumor in the peritoneal cavity of Swiss mice inoculated with Ehrlich ascites tumor, treated with 50 mg/kg and 
75 mg/kg of SZTP-14 and sacrificed 55 days after tumor inoculation
Treatment
75 mg/kg ? 75 mg/kg ? 50 mg/kg ? 50 mg/kg ?
Ascites ml - - 0 - 4 1 6 - 0 - - 5 2 4 0 - 1 - 4 0
Solid tumor in the 
abdominal cavity
+ + 0 + + + + + 0 + + + + + 0 + + + + 0
0: the animal died earlier, +: solid tumor in the abdominal cavity, - : no ascitesCancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/4
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cause increase or decrease of cell number even in a high
dose (100 µg/ml).
In vivo experiments: the effect of SZTP-14 on tumor 
growth and metastasis L1210 tumor
Table 3 shows that the survival of treated animals exceed-
ed that of the controls. Ten days after the tumor inocula-
tion not a single control mouse was alive. At the same
time all treated animals were alive. The first treated animal
died 13 days, the last one 15 days after tumor inoculation.
Ehrlich ascites tumor
Table 4 shows the survival of mice from 16 days after tu-
mor inoculation. The control animals died between 17
and 22 days. In each treated group the animals were alive
(except one/group) 55 days after tumor inoculation,
when the animals were sacrificed. Table 5 shows the
amount of ascites and the presence of solid tumor in the
peritoneal cavity. This means that no tumor-free animal
was found, but out of 20 treated mice 16 were alive 33
days after the death of the last control mouse. No differ-
ence in response to SZTP-14 treatment regarding gender
was observed.
P 388 tumor
All control mice died by day 10 following tumor inocula-
tion. The treated mice all survived until day 15, but all
died by day 18 (Table 6).
Lewis lung tumor
Spleen-liver model
Table 7 shows the number of liver metastases. Not a single
liver metastasis was found after SZTP-14 treatment,
whereas 20–63 metastatic nodules were found in control
animals.
Muscle-lung model
The number and average volume of lung metastases are
shown in Table 8. SZTP-14 treatment significantly de-
creased the number and average volume of lung metastas-
es.
Discussion
Our studies revealed that among the poly-L-isolysines
(polymerisation degree:10–400) prepared by our meth-
od, the polymers of polymerisation degree 40–200 (Mw
5.5–20.3 KD) retarded cell proliferation; i.e. they showed
antitumor activity in vitro and in vivo, and inhibited the
formation of tumor metastases. The antitumor effect was
dependent on the degree of polymerisation.
In vitro, SZTP-14 and some other peptides decreased the
number of tumor cells dose-dependently when compared
to the control. This effect appeared as stagnation of cell
number in case of small doses, whereas high doses killed
cells. Isopolylysines K 17 and H 17 were ineffective, α -
polylysine only led to static cell numbers.
In vivo treatment with SZTP-14 increased the survival of
the treated animals inoculated with L1210, P 388 and
Ehrlich ascites tumor. In the case of Ehrlich tumor, the
treatment caused a very long tumor-free period and tumor
growth was observed only after the cessation of treatment.
Table 6: The effect of 10 mg/kg daily SZTP-14 treatment on the 
survival of BDF/1 mice inoculated with P-388 ascites tumor
Days after inocula-
tion












Table 7: Effect of SZTP-14 treatment (75 mg/kg intraperitoneally for 8 days) on liver metastases in female C57 Bl mice inoculated with 
LLT into the spleen
Number of liver metastases
C o n t r o l 3 12 06 33 63 85 6
(ξ  = 40.66; s = 16.02; n = 6)
SZTP-14 0 0 0 0 (n = 4)Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/4
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After SZTP treatment no metastasis formation was seen in
the liver when the tumor was inoculated into the spleen,
and there was a decrease in the number and size of lung
metastases when the tumor was inoculated into the mus-
cle.
The compounds with Mw 10.2–15.4 kD (polymerisation
degree 80–120) showed the highest activity, surpassing
that of clavicepamines [3]. The other substances tested
were ineffective, presumably because of high polydisper-
sity, low Mw and racemization. The results of this study
indicate that peptides with promising biological effects
can be synthesized with high reproducibility.
Although alpha-poly-L-lysine is known as a cell prolifera-
tion enhancing agent [2], L-lysine has been reported to
have inhibitory effect on the growth of several transplant-
able animal tumors [7]. D-lysine, however, and methylat-
ed derivatives of L-lysine enhance cell proliferation under
various experimental conditions [8]. The antitumor activ-
ity of TNF-alpha is likely to depend on the lysine amino
groups of this compound [9]. Our studies indicate that ep-
silon-poly-L-lysine inhibits proliferation of several tumor
lines, in vitro and in vivo. The in vivo effectiveness of this
peptide indicates a direct effect on tumor cells, but in the
case of in vivo experiments the immunostimulatory activi-
ty cannot be excluded as at least a contributor to the tu-
mor growth inhibiting activity. The presence of other
amino acids (Glu, Phe, Gly, Asp, Met) seems unnecessary
and the change of Lys to Orn did not to improve the ef-
fects.
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